Mark Carol, M.d.
surgery
SONACARE HQ
Australia
Biography
Chief Executive Officer & President Dr. Mark Carol is a neurosurgeon with over 30 years' experience in the medical device and health care services arenas in publicly traded and privately held companies. Widely viewed as the "father of IMRT" and a household name in Radiation Oncology, he has a proven track record of taking nascent disruptive technology, in multiple disparate fields, from conceptualization through commercialization. He was the founder and CEO of NOMOS Corporation, the "first mover" in the development of 3 paradigm shifting technologies in radiation oncology, intensity modulated radiation therapy, inverse treatment planning and image-guided therapy. He was also the CMO of Xoft, Inc., and Alliance Oncology, where he developed clinical program strategies for miniature x-ray sources used to deliver therapeutic ionizing radiation (Xoft), and developed novel oncology treatments sites through JV or direct ownership (Alliance). Dr. Carol held development & consulting Medical Director positions with large NYSE and NASDAQ companies, such as Varian Medical Systems, Accuray Incorporated and Siemens Oncology.
Research Interest
Chief Executive Officer & President Dr. Mark Carol is a neurosurgeon with over 30 years' experience in the medical device and health care services arenas in publicly traded and privately held companies. Widely viewed as the "father of IMRT" and a household name in Radiation Oncology, he has a proven track record of taking nascent disruptive technology, in multiple disparate fields, from conceptualization through commercialization. He was the founder and CEO of NOMOS Corporation, the "first mover" in the development of 3 paradigm shifting technologies in radiation oncology, intensity modulated radiation therapy, inverse treatment planning and image-guided therapy. He was also the CMO of Xoft, Inc., and Alliance Oncology, where he developed clinical program strategies for miniature x-ray sources used to deliver therapeutic ionizing radiation (Xoft), and developed novel oncology treatments sites through JV or direct ownership (Alliance). Dr. Carol held development & consulting Medical Director positions with large NYSE and NASDAQ companies, such as Varian Medical Systems, Accuray Incorporated and Siemens Oncology.
